Levi & Korsinsky, LLP announces that a BLU class action lawsuit has been filed on behalf of investors who purchased BELLUS Health Inc.  (BLU) securities between September 5, 2019 and July 5, 2020. For more on the BLU Lawsuit please contact us today.

According to the BELLUS Health lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: while BLU-5937’s “high selectivity” contributed to the drug causing little to no taste alteration in chronic cough patients, that high selectivity also contributed to the drug potentially being less efficacious and thus likely not be able to meet the primary endpoint of the Company’s Phase 2 trial.

TO LEARN MORE ABOUT THE BLU CLASS ACTION LAWSUIT, CLICK HERE

If you suffered a loss in BELLUS Health you have until May 17, 2021, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com